Vincent P Mihalik insider trades: Amylin Pharmaceuticals (AMLN) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Vincent reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 1, 2012 | AMLN | ↓ Sell | 1,231 | $17.11 | $21K | Direct | Mar 2, 2012 (1d) |
| Feb 23, 2012 | AMLN | ↓ Sell | 7,518 | $17.03 | $128K | Direct | Feb 24, 2012 (1d) |
| Feb 8, 2012 | AMLN | ↓ Sell | 3,842 | $16.62 | $64K | Direct | Feb 10, 2012 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Vincent P Mihalik's insider trades
Vincent P Mihalik is SVP, Chief Commercial Officer at Amylin Pharmaceuticals (AMLN). Since Feb 8, 2012, Vincent has reported no open-market purchases and 3 sales worth $213K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (8 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AMLN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.